Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

25401 BCR/ABL, p210, RT-PCR(BCRAB)

BCR/ABL, p210, RT-PCR(BCRAB)
Test Code: BCRAMSO
Synonyms/Keywords
​Chronic Myelogenous Leukemia (CML), CML (Chronic Myelogenous Leukemia), CML RT-PCR,  Philadelphia Chromosome Ph1 Bone Marrow/Blood, Chronic Myeloid Leukemia, BCR/ABL 1, CML monitoring, Tyrosine kinase inhibitor (TKI) therapy monitoring
Useful For
​MONITORING response to therapy in patients with chronic myeloid leukemia who are known to have the e13/a2 or e14/a2 BCR/ABL 1 fusion transcript forms
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
​​(no repeat)
​​​No ​Whole Blood ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​10 ml ​4 mL ​
​                                                                                        OR
​No ​Bone Marrow ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​3 mL ​1 mL ​
Collection Processing Instructions

Pertinent clinical history is required, including if the patient has a diagnosis of chronic myelogenous leukemia or other bcr/abl-positive neoplasm.

 Notify Cytogenetics (1-800-222-5835, ext 16388) when specimen is collected.

Acceptable Specimen Types
​Whole Blood OR Bone Marrow
Specimen Stability Information
Specimen Type Temperature Time​​

​Whole Blood

OR

Bone Marrow

​

​Refrigerated

(preferred)

 ​72 hours
​Room Temperature ​72 hours
Rejection Criteria
Whole Blood Gross Hemolysis​​
Bone Marrow​ ​Gross Hemolysis
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation​​
Mayo Medical Laboratories​ ​Monday through Friday ​3 days ​RT-PCR using GeneXpert
Reference Lab
Mayo Clinic Laboratories
Reference Range Information
Performing Location Reference Range​​
Mayo Medical Laboratories​ ​Interpretive Report
Interpretation
​An interpretive report will be provided. When bcr/abl mRNA is present, quantitative results are reported on the international scale, established from data originally reported in the IRIS (International Randomized Study of Interferon versus STI571) trial involving newly diagnosed chronic myeloid leukemia patients. Using the international scale, a result <0.1% bcr/abl1(p210):ABL1 is equivalent to a major molecular remission.  This value is also designated on a log scale (Molecular Response, MR) as MR3. 
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comment​​s
81206​ ​ ​ ​ ​
Synonyms/Keywords
​Chronic Myelogenous Leukemia (CML), CML (Chronic Myelogenous Leukemia), CML RT-PCR,  Philadelphia Chromosome Ph1 Bone Marrow/Blood, Chronic Myeloid Leukemia, BCR/ABL 1, CML monitoring, Tyrosine kinase inhibitor (TKI) therapy monitoring
Ordering Applications
Ordering Application Descripti​​on
Clinical Order Manager​ ​BCR/ABL, p210, Qnt Therapeutic
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
​​(no repeat)
​​​No ​Whole Blood ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​10 ml ​4 mL ​
​                                                                                        OR
​No ​Bone Marrow ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​3 mL ​1 mL ​
Collection Processing

Pertinent clinical history is required, including if the patient has a diagnosis of chronic myelogenous leukemia or other bcr/abl-positive neoplasm.

 Notify Cytogenetics (1-800-222-5835, ext 16388) when specimen is collected.

Acceptable Specimen Types
​Whole Blood OR Bone Marrow
Specimen Stability Information
Specimen Type Temperature Time​​

​Whole Blood

OR

Bone Marrow

​

​Refrigerated

(preferred)

 ​72 hours
​Room Temperature ​72 hours
Rejection Criteria
Whole Blood Gross Hemolysis​​
Bone Marrow​ ​Gross Hemolysis
Useful For
​MONITORING response to therapy in patients with chronic myeloid leukemia who are known to have the e13/a2 or e14/a2 BCR/ABL 1 fusion transcript forms
Reference Range Information
Performing Location Reference Range​​
Mayo Medical Laboratories​ ​Interpretive Report
Interpretation
​An interpretive report will be provided. When bcr/abl mRNA is present, quantitative results are reported on the international scale, established from data originally reported in the IRIS (International Randomized Study of Interferon versus STI571) trial involving newly diagnosed chronic myeloid leukemia patients. Using the international scale, a result <0.1% bcr/abl1(p210):ABL1 is equivalent to a major molecular remission.  This value is also designated on a log scale (Molecular Response, MR) as MR3. 
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation​​
Mayo Medical Laboratories​ ​Monday through Friday ​3 days ​RT-PCR using GeneXpert
Reference Lab
Mayo Clinic Laboratories
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comment​​s
81206​ ​ ​ ​ ​
For most current information refer to the Marshfield Laboratory online reference manual.